Compare INSM & AXON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSM | AXON |
|---|---|---|
| Founded | 1988 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ordnance And Accessories |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2B | 49.3B |
| IPO Year | 2000 | N/A |
| Metric | INSM | AXON |
|---|---|---|
| Price | $156.33 | $611.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 23 | 14 |
| Target Price | $188.71 | ★ $800.23 |
| AVG Volume (30 Days) | ★ 2.6M | 579.9K |
| Earning Date | 02-19-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.13 |
| Revenue | $447,022,000.00 | ★ $2,557,957,000.00 |
| Revenue This Year | $49.51 | $34.12 |
| Revenue Next Year | $134.47 | $25.56 |
| P/E Ratio | ★ N/A | $195.96 |
| Revenue Growth | 30.34 | ★ 32.01 |
| 52 Week Low | $60.40 | $469.24 |
| 52 Week High | $212.75 | $885.92 |
| Indicator | INSM | AXON |
|---|---|---|
| Relative Strength Index (RSI) | 34.08 | 52.63 |
| Support Level | $153.19 | $595.54 |
| Resistance Level | $164.62 | $649.30 |
| Average True Range (ATR) | 7.67 | 23.69 |
| MACD | -0.76 | -1.62 |
| Stochastic Oscillator | 9.60 | 53.62 |
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Axon Enterprise Inc is building a public safety operating system by integrating a suite of hardware devices and cloud software solutions. The company's suite includes cloud-hosted digital evidence management solutions, productivity and real-time operations software, body cameras, in-car cameras, TASER energy devices, drones and robotic security, and training solutions. The company's operation comprises of two operating segments, Software and Sensors, and TASER. The company generates the majority of its revenue from the Software and Sensors segment, which is engaged in developing, manufacturing, and selling fully integrated hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.